Browse
Submit Data
Databases
API
Help

Dataset Information

0 Views

0 Connections

0 Citations

0 Reanalyses

0 Downloads

Omics score: 0

ABSTRACT: Measurable Residual IDH2 before Allogeneic Transplant for Acute Myeloid Leukemia

PROVIDER: PRJNA1051602 | ENA |

REPOSITORIES: ENA

ACCESS DATA

Json Xml

Dataset's files

Source:

			Action	DRS
	SRR27187100_1.fastq.gz	Fastqsanger.gz
	SRR27187100_2.fastq.gz	Fastqsanger.gz
	SRR27187101_1.fastq.gz	Fastqsanger.gz
	SRR27187101_2.fastq.gz	Fastqsanger.gz
	SRR27187102_1.fastq.gz	Fastqsanger.gz

Items per page:

1 - 5 of 106

Similar Datasets

Project description:Measurable Residual IDH1 before Allogeneic Transplant for Acute Myeloid Leukemia

| PRJNA997373 | ENA

Project description:Measurable Residual FLT3-ITD before Allogeneic Transplant for Acute Myeloid Leukemia

| PRJNA1021545 | ENA

Project description:FLT3-TKD measurable residual disease in acute myeloid leukemia

| PRJNA979814 | ENA

Project description:Measurable Residual Disease in IDH mutated Acute Myeloid Leukemia patients

| PRJNA998386 | ENA

Mechanisms of response and resistance to combined decitabine and ipilimumab for advanced myeloid disease

Project description:The ETCTN 10026 study tested decitabine and ipilimumab for transplant-naive advanced myelodysplastic syndrome/acute myeloid leukemia and relapsed acute myeloid leukemia after allogeneic hematopoietic stem cell transplantation. Using single cell RNA sequencing, determinants of response (higher T/NK to myeloid cell ratio in responders) and resistance (insufficient clearance of AML clones) were identified and pharmacodynamics of decitabine (cytoreduction) and ipilimumab (increase in regulatory T cells) characterized.

2023-10-31 | GSE223844 | GEO

Investigation of Measurable Residual Disease in Acute Myeloid Leukemia by DNA Methylation Patterns

Project description:Investigation of Measurable Residual Disease in Acute Myeloid Leukemia by DNA Methylation Patterns

| PRJNA699877 | ENA

Benefit of allograft in persistent mutations in NK-AML

Project description:Allogeneic transplant can abrogate the risk of relapse in the patients of first remission acute myeloid leukemia with detectable measurable residual disease by next-generation sequencing

| PRJEB32367 | ENA

Single Cell Genotypic and Phenotypic Analysis of Measurable Residual Disease in Acute Myeloid Leukemia

Project description:Single Cell Genotypic and Phenotypic Analysis of Measurable Residual Disease in Acute Myeloid Leukemia

| PRJNA947747 | ENA

Project description:Targeted RNA-sequencing for the quantification of measurable residual disease in acute myeloid leukemia

| PRJNA421563 | ENA

Single Cell Genotypic and Phenotypic Analysis of Measurable Residual Disease in Acute Myeloid Leukemia

Project description:Single Cell Genotypic and Phenotypic Analysis of Measurable Residual Disease in Acute Myeloid Leukemia

| PRJNA947748 | ENA